Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb & the Cancer Research Institute Announce Collaboration to Acc...
March 28 2017 - 6:59AM
Business Wire
- Innovative collaboration model
designed to accelerate next-generation precision cancer
immunotherapy through network of leading research centers and top
scientists
- Collaboration will leverage
efficiencies in cancer research to rapidly implement novel
Immuno-Oncology clinical studies
- Bristol-Myers Squibb is the first
industry partner to join a collaboration with the Parker Institute
and the Cancer Research Institute
The Parker Institute for Cancer Immunotherapy, Bristol-Myers
Squibb Company (NYSE: BMY) and the Cancer Research Institute (CRI)
today announced a multi-year clinical research collaboration to
coordinate and rapidly initiate clinical Immuno-Oncology (I-O)
studies across the Parker Institute and CRI networks. Bristol-Myers
Squibb will work closely with leading Parker Institute and CRI
scientists and researchers, soliciting clinical research proposals
from their networks and coordinating multi-site collaboration
clinical studies to pursue some of the most difficult questions in
cancer research. It will provide scientists with an ecosystem of
advanced translational tools, precision immunotherapy and
cutting-edge bioanalytical expertise to maximize learning and
ensure the generation of high quality data to inform future
development.
The Parker Institute is a novel collaboration model which
includes industry, academic and philanthropic participants, focused
on the shared goal of accelerating immunotherapy research to
develop and deliver new treatment options for patients. CRI is a
nonprofit organization dedicated to advancing laboratory and
clinical research through its global network of academic, industry,
and nonprofit partners with the goal of developing lifesaving
immunotherapies for all forms of cancer.
The collaboration will build on the Parker Institute model that
brings together the nation’s top research institutions to share
resources, data and technology to accelerate research through
unifying and managing clinical trial design and conducting clinical
studies across multi-centers. The Parker Institute currently funds
projects across its network of more than 60 laboratories and 300
researchers who work together to advance research and potentially
develop new therapies. The Cancer Research Institute will support
the collaboration with investment from its Clinical Accelerator
venture philanthropy program and access to its global network of
leading investigators from around the world.
“Bristol-Myers Squibb is initiating this unique collaboration
with a goal of accelerating the identification and development of
new treatment options for patients who are facing very serious
disease,” said Fouad Namouni, M.D., head of Oncology Development,
Bristol-Myers Squibb. “We are excited to partner with the Parker
Institute and the Cancer Research Institute to leverage the unique
translational capabilities of their networks and explore novel
mechanisms of action in the field of I-O.”
This is the Parker Institute’s first major agreement with a
biopharma partner. The institute will continue to build key
industry relationships critical for the success of its unique
model.
“One of our goals is to help facilitate collaborations between
academia and industry to help advance cancer research,” said
Jeffrey Bluestone, Ph.D., CEO and president of the Parker Institute
for Cancer Immunotherapy. “Partnering with Bristol-Myers Squibb, a
renowned leader in the field of immuno-oncology development, is a
major leap forward for us. We could not be more enthusiastic to
start this collaboration, which we believe will accelerate the
process of turning important lab discoveries by our investigators
into the potential for much needed treatments for patients.”
“Unlocking the full potential of next-generation precision
cancer immunotherapy requires the kind of coordination, resources,
and logistical support that the Parker Institute and the Cancer
Research Institute can offer our research partners, and
collaboration with industry leaders like Bristol-Myers Squibb will
be essential to hastening the development of new cancer
immunotherapies,” said Jill O’Donnell-Tormey, Ph.D., CEO and
director of scientific affairs at CRI.
Bristol-Myers Squibb &
Immuno-Oncology: Advancing Oncology Research
At Bristol-Myers Squibb, patients are at the center of
everything we do. Our vision for the future of cancer care is
focused on researching and developing transformational
Immuno-Oncology (I-O) medicines that will raise survival
expectations in hard-to-treat cancers and will change the way
patients live with cancer.
We are leading the scientific understanding of I-O through our
extensive portfolio of investigational and approved agents and our
differentiated clinical development program, which is studying
broad patient populations across more than 35 types of cancers with
13 clinical-stage molecules designed to target different immune
system pathways. Our deep expertise and innovative clinical trial
designs uniquely position us to advance the science of combinations
across multiple tumors and potentially deliver the next wave of I-O
combination regimens with a sense of urgency. We also continue to
pioneer research that will help facilitate a deeper understanding
of the role of immune biomarkers and inform which patients will
benefit most from I-O therapies.
We understand making the promise of I-O a reality for the many
patients who may benefit from these therapies requires not only
innovation on our part but also close collaboration with leading
experts in the field. Our partnerships with academia, government,
advocacy and biotech companies support our collective goal of
providing new treatment options to advance the standards of
clinical practice.
About Bristol-Myers
Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose
mission is to discover, develop and deliver innovative medicines
that help patients prevail over serious diseases. For more
information about Bristol-Myers Squibb, visit us at BMS.com or
follow us on LinkedIn, Twitter, YouTube and Facebook.
About Parker Institute for Cancer
Immunotherapy
The Parker Institute for Cancer Immunotherapy brings together
the best scientists, clinicians and industry partners to build a
smarter and more coordinated cancer immunotherapy research effort.
The Parker Institute is an unprecedented collaboration between the
country’s leading immunologists and cancer centers, including
Memorial Sloan Kettering Cancer Center, Stanford Medicine, the
University of California, Los Angeles, the University of
California, San Francisco, the University of Pennsylvania and The
University of Texas MD Anderson Cancer Center. The Parker Institute
network also includes more than 40 industry and nonprofit partners,
more than 60 labs and more than 300 of the nation’s top researchers
focused on treating the deadliest cancers.
The goal is to accelerate the development of breakthrough immune
therapies capable of turning most cancers into curable diseases.
The institute was created through a $250 million grant from The
Parker Foundation. For more information, visit parkerici.org.
About the Cancer Research
Institute
The Cancer Research Institute (CRI), established in 1953, is the
world’s leading nonprofit organization dedicated exclusively to
transforming cancer patient care by advancing scientific efforts to
develop new and effective immune system-based strategies to
prevent, diagnose, treat, and eventually cure all cancers. Guided
by a world-renowned Scientific Advisory Council that includes three
Nobel laureates and 26 members of the National Academy of
Sciences, CRI has invested $336 million in support of
research conducted by immunologists and tumor immunologists at the
world’s leading medical centers and universities, and has
contributed to many of the key scientific advances that demonstrate
the potential for immunotherapy to change the face of cancer
treatment. To learn more, go to cancerresearch.org.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170328005529/en/
Bristol-Myers Squibb:Media:Ken Dominski,
609-252-5251ken.dominski@bms.comorLisa McCormick Lavery,
609-252-7602lisa.mccormicklavery@bms.comorInvestors:Tim
Power, 609-252-7509timothy.power@bms.comorBill Szablewski,
609-252-5894william.szablewski@bms.comorParker Institute for
Cancer Immunotherapy:Shirley Dang, 415-930-4385 (work),
415-374-9987 (cell)sdang@parkerici.orgorCancer Research
Institute:W2O GroupElliot Fox,
212-257-6724efox@w2ogroup.com
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024